{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T14:04:12Z","timestamp":1748009052337},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"\n Background:<\/jats:title>\n Previous studies have reported inconsistent findings regarding the impact of the UGT1A4*3<\/jats:italic> variant allele on lamotrigine (LTG) exposure. As no studies have controlled for nongenetic factors, the aim of this study was to compare serum concentrations of LTG in carriers versus noncarriers of UGT1A4*3<\/jats:italic> adjusting for differences in age, sex, and valproic acid (VPA) comedication.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Matched data on serum concentration of LTG and UGT1A4<\/jats:italic> genotype patients with known information about VPA comedication were included retrospectively from a therapeutic drug monitoring service. Linear mixed-model analysis was used to evaluate the impact of the UGT1A4*3<\/jats:italic> variant on dose-adjusted serum concentrations (C\/D ratio) of LTG. Subanalyses were performed to assess the impact of UGT1A4*3<\/jats:italic> in relation to age, sex, and VPA comedication.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n In total, 534 patients (1735 LTG serum concentrations) were included. In the study population, UGT1A4*3<\/jats:italic> carriers (n = 87; 16.3%) were estimated to have a 13% lower LTG C\/D ratio compared with noncarriers (P<\/jats:italic> = 0.01). Subanalyses showed that the quantitative impact of UGT1A4*3<\/jats:italic> was greatest in postmenopausal women (>50 years) without VPA comedication. In these patients (n = 99), UGT1A4*3<\/jats:italic> carriers displayed a 40% lower LTG C\/D ratio than noncarriers (P<\/jats:italic> = 0.001). The UGT1A4*3<\/jats:italic> variant had no significant effect on LTG C\/D ratio in the other subpopulations (P<\/jats:italic> > 0.1). Regardless of patient subgroup, the concomitant use of VPA was the strongest determinant of LTG exposure by increasing the C\/D ratio 2.5-fold (P<\/jats:italic> < 0.001).<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n This study shows that UGT1A4*3<\/jats:italic> generally has a modest impact on LTG exposure, but it could lead to clinically relevant lowering in LTG serum concentration among postmenopausal women. The clinical impact of UGT1A4*3<\/jats:italic> in these patients needs to be assessed in relation to comedication with VPA, which is associated with a substantial increase in serum concentration of LTG.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000540","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T22:18:38Z","timestamp":1533248318000},"page":"567-571","source":"Crossref","is-referenced-by-count":7,"title":["Clinically Relevant Effect of UGT1A4*3 on Lamotrigine Serum Concentration Is Restricted to Postmenopausal Women\u2014A Study Matching Therapeutic Drug Monitoring and Genotype Data From 534 Patients"],"prefix":"10.1097","volume":"40","author":[{"given":"Robert L.","family":"Smith","sequence":"first","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tore","family":"Haslemo","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde F.","family":"Chan","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"},{"name":"School of Pharmacy, University of Oslo, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge","family":"Refsum","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"},{"name":"School of Pharmacy, University of Oslo, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?","volume":"45","author":"Johannessen","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/FPC.0b013e3283331637","article-title":"A pharmacogenetics study of the human glucuronosyltransferase UGT1A4","volume":"19","author":"Benoit-Biancamano","year":"2009","journal-title":"Pharmacogenet Genomics."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/hep.20131","article-title":"Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4","volume":"39","author":"Ehmer","year":"2004","journal-title":"Hepatology."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","article-title":"Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants","volume":"21","author":"Erickson-Ridout","year":"2011","journal-title":"Pharmacogenet Genomics."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/clpt.2012.46","article-title":"UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems","volume":"92","author":"Haslemo","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","article-title":"Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China","volume":"70","author":"Chang","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","article-title":"The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy","volume":"95","author":"Gulcebi","year":"2011","journal-title":"Epilepsy Res."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","article-title":"Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children","volume":"71","author":"Liu","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","article-title":"Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients","volume":"69","author":"Singkham","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters","volume":"82","author":"Milosheska","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2217\/pgs.11.105","article-title":"Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes","volume":"12","author":"Zhou","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/00007691-200012000-00003","article-title":"Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage?","volume":"22","author":"Morris","year":"2000","journal-title":"Ther Drug Monit."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","article-title":"Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy","volume":"30","author":"Rivas","year":"2008","journal-title":"Ther Drug Monit."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","article-title":"Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure\u2013an impact similar to male gender or smoking in schizophrenic patients","volume":"66","author":"Ghotbi","year":"2010","journal-title":"Eur J Clin Pharmacol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1528-1167.2007.00997.x","article-title":"Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial","volume":"48","author":"Christensen","year":"2007","journal-title":"Epilepsia."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00007691-199904000-00006","article-title":"Lamotrigine drug interactions in a TDM material","volume":"21","author":"Bottiger","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0140-6736(93)93048-6","article-title":"Interaction of lamotrigine with sodium valproate","volume":"341","author":"Panayiotopoulos","year":"1993","journal-title":"Lancet."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:23:02Z","timestamp":1692051782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000540","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}